Literature DB >> 10600608

The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis.

C Risco1, J R Rodríguez, W Demkowicz, R Heljasvaara, J L Carrascosa, M Esteban, D Rodríguez.   

Abstract

The vaccinia virus (VV) 39-kDa protein, the product of the A4L gene, is a highly antigenic protein of the viral core. Pulse-chase and immunoprecipitation experiments have shown that the 39-kDa protein interacts with p4a (encoded by the A10L gene), the precursor of the most abundant virion protein. This interaction is maintained with the processed 4a form that arises during virion maturation. The controlled disruption of mature viral particles showed that the 39-kDa and 4a proteins are tightly bound within the virion. Immunoelectron microscopy showed that both proteins first localize within the cytoplasm and later accumulate inside the viral factories, reaching these locations via a mechanism apparently unrelated to cellular membranes. Double labeling experiments showed a colocalization of both proteins in all virus-induced structures. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600608     DOI: 10.1006/viro.1999.0046

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Identification of 10 cowpox virus proteins that are necessary for induction of hemorrhagic lesions (red pocks) on chorioallantoic membranes.

Authors:  Zhiyong Xu; Dimitrios Zikos; Aistė Tamošiūnaitė; Robert Klopfleisch; Nikolaus Osterrieder; B Karsten Tischer
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 4.  A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication.

Authors:  Christopher Netherton; Katy Moffat; Elizabeth Brooks; Thomas Wileman
Journal:  Adv Virus Res       Date:  2007       Impact factor: 9.937

5.  Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells.

Authors:  Juan Carlos Gallego-Gómez; Cristina Risco; Dolores Rodríguez; Pilar Cabezas; Susana Guerra; José L Carrascosa; Mariano Esteban
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Vaccinia virus protein A3 is required for the production of normal immature virions and for the encapsidation of the nucleocapsid protein L4.

Authors:  Desyree Murta Jesus; Nissin Moussatche; Baron B D McFadden; Casey Paulasue Nielsen; Susan M D'Costa; Richard C Condit
Journal:  Virology       Date:  2015-03-09       Impact factor: 3.616

7.  Fine structure of the vaccinia virion determined by controlled degradation and immunolocalization.

Authors:  Nissin Moussatche; Richard C Condit
Journal:  Virology       Date:  2014-12-08       Impact factor: 3.616

8.  Vaccinia virus J1R protein: a viral membrane protein that is essential for virion morphogenesis.

Authors:  Wen-Ling Chiu; Wen Chang
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections.

Authors:  Elena Domingo-Gil; Eva Pérez-Jiménez; Iván Ventoso; José L Nájera; Mariano Esteban
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

10.  Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.

Authors:  Eric F Tewalt; Jean M Grant; Erica L Granger; Douglas C Palmer; Neal D Heuss; Dale S Gregerson; Nicholas P Restifo; Christopher C Norbury
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.